Joseph Defraites
Family · New Orleans, LANPI 1104381748
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,206 of the $12,548 with a category attached, or 81.3%. 36 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 29.6% of the total. 2025 is the largest year on record at $6,767, 6.5 times the $1,037 reported in 2021. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $51.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$4K
- AstraZeneca$3K
- Sanofi$2K
- GSK$760
- Amgen$363
- Grifols USA, LLC$286
- plus $3K from 30 others
What the payments were for
- Consulting fees$2,08817%
- Travel & lodging$2542%
- Food & beverage$10,20681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 46 | $3,710 |
| AstraZeneca(2 entities) | 43 | $2,824 |
| Sanofi | 24 | $1,592 |
| GSK | 42 | $760 |
| Amgen | 10 | $363 |
| Grifols USA, LLC | 10 | $286 |
| Dexcom, Inc. | 2 | $272 |
| Teva Pharmaceuticals USA, Inc. | 2 | $247 |
| Gilead | 2 | $223 |
| Viatris Specialty LLC | 4 | $194 |
| Neurelis, Inc. | 2 | $176 |
| Insmed, Inc. | 4 | $174 |
| Boehringer Ingelheim | 4 | $158 |
| Verona Pharma, Inc. | 7 | $149 |
| Organon | 1 | $138 |
| Mylan Specialty L.p. | 6 | $133 |
| Madrigal Pharmaceuticals | 1 | $123 |
| Viiv Healthcare Company | 1 | $121 |
| Idorsia Pharmaceuticals US Inc | 1 | $120 |
| AbbVie | 6 | $113 |
| Electromed, Inc. | 5 | $99 |
| Jazz Pharmaceuticals Inc. | 1 | $97 |
| Baxter Healthcare | 3 | $85 |
| Boston Scientific | 1 | $71 |
| Shionogi Inc | 1 | $52 |
| UCB, Inc. | 2 | $42 |
| Genentech USA, Inc. | 1 | $33 |
| Philips North America LLC | 2 | $29 |
| Pulmonx Corporation | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Apria Healthcare LLC | 2 | $24 |
| Alcresta Therapeutics, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| 3b Medical, Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Sandoz | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$3,251
- FASENRA$625
- TEZSPIRE$619
- BREZTRI$617
- NUCALA$247
- DEXCOM G7 GSS (161)$154
- Prolastin-C Liquid$153
- VTAMA$138
- FABRAZYME$125
- AJOVY$125
- Epclusa$125
- NEXVIAZYME$124
- REZDIFFRA$123
- Yupelri$123
- Austedo XR$122
- DOVATO$121
- Ohtuvayre$121
- QUVIVIQ$120
- DEXCOM G6 TRANSMITTER$117
- Arikayce$102
How this compares
$12,548 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 51 | $194,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 169 | $125,864 |
| Fasenra PenBenralizumab | 19 | $106,330 |
| XolairOmalizumab | 14 | $58,596 |
| Spiriva RespimatTiotropium Bromide | 46 | $29,842 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $25,348 |
| Spiriva HandihalerTiotropium Bromide | 24 | $13,842 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,312 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $8,089 |
| Roflumilast | 65 | $6,367 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,297 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,064 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 182 | $5,446 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,961 |
| Azelastine Hcl | 51 | $2,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $760 | $141,473201 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $158 | $63,279109 claims |
| AstraZenecaSymbicort | $2,824 | $6,06425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in New Orleans
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Amy SchmittNew Orleans$48K
- Eric BabineauxNew Orleans$32K
- Cherie AlbroNew Orleans$29K
- Aimee ScroggsNew Orleans$20K
- Kelly BaquetNew Orleans$18K
- Lori LemoineNew Orleans$17K
- Jennifer GreenheckNew Orleans$15K
- Rebecca EzellSlidell$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.